Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

8295	Companies
114850	Keywords
55292	Articles
62440	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 10/17/2024 at 18:00, 1 month 3 days ago

THERANEXUS S'ASSOCIE À SYNERLAB POUR PRÉPARER LA COMMERCIALISATION DE SA FORMULATION PÉDIATRIQUE DANS LA MALADIE DE NIEMANN-PICK DE TYPE C
Theranexus et Synerlab annoncent un partenariat pour la production du traitement Mig-OS pour la maladie de Niemann-Pick de type C. Lancement commercial prévu dès 2026

Theranexus EMA Synerlab Mig-OS Maladie De Niemann-Pick De Type C
PRESS RELEASE

published on 10/17/2024 at 18:00, 1 month 3 days ago

THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE
Theranexus partners with Synerlab to produce oral solution of miglustat for Niemann-Pick type C disease, aiming for EMA approval and commercialization by 2026. Novel pediatric formulation Mig-OS provides new therapeutic option for NPC patients

Theranexus Synerlab Miglustat Niemann-Pick Type C Disease EMA Approval
BRIEF

published on 09/26/2024 at 18:05, 1 month 24 days ago

Theranexus annonce ses résultats financiers du premier semestre 2024

Résultats Financiers Biopharmaceutique Réduction Des Coûts Theranexus Batten-1
BRIEF

published on 09/26/2024 at 18:05, 1 month 24 days ago

Theranexus announces its financial results for the first half of 2024

Financial Results Cost Reduction Biopharmaceutical Theranexus Batten-1
PRESS RELEASE

published on 09/26/2024 at 18:00, 1 month 24 days ago

THERANEXUS ANNOUNCES FIRST HALF 2024 FINANCIAL RESULTS
Theranexus reports cost reduction success and positive first half 2024 financial results, led by completion of Batten-1 clinical trial and operating grants

Financial Results Cost Reduction Clinical Trial Theranexus Batten-1
PRESS RELEASE

published on 09/26/2024 at 18:00, 1 month 24 days ago

THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2024
Theranexus, société biopharmaceutique, annonce ses résultats semestriels 2024. Baisse significative des charges d'exploitation grâce à la fin d'essais cliniques et efforts de réduction des coûts

Résultats Semestriels Biopharmaceutique Réduction Des Coûts Theranexus Maladies Neurologiques
BRIEF

published on 07/11/2024 at 18:50, 4 months 9 days ago

Theranexus annonce sa trésorerie au 30 juin 2024 et détaille le progrès de Batten-1

Financement Trésorerie Theranexus Batten-1 Maladie Neurologique
BRIEF

published on 07/11/2024 at 18:50, 4 months 9 days ago

Theranexus announces its cash flow as of June 30, 2024 and details the progress of Batten-1

Treasury Funding Theranexus Batten-1 Neurological Disease
PRESS RELEASE

published on 07/11/2024 at 18:45, 4 months 9 days ago

Theranexus publie sa trésorerie au 30 juin 2024 et fait le point sur l'avancement de Batten-1
Theranexus publie sa trésorerie au 30 juin 2024, avance sur Batten-1 et ouvre nouvelle ligne de financement en fonds propres. Commercialisation phase 3 Batten-1 en vue

Financement Trésorerie Fonds Propres Theranexus Batten-1
PRESS RELEASE

published on 07/11/2024 at 18:45, 4 months 9 days ago

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included

Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line

Accesswire

Published on 11/21/2024 at 11:30, 30 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 57 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 3 hours ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 25 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:30, 30 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 59 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 1 hour ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 1 hour 3 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 30 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 2 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 2 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 2 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 52 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 40 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE